Humacyte, Inc.
HUMANext catalyst
Acellular Tissue Engineered Vessel (ATEV)
End Stage Renal Disease (ESRD)
Get an email about HUMA's next catalysts
Track Humacyte (HUMA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
HUMA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.09 | FQ end Sep/2026 | Call: bmo
Acellular Tissue Engineered Vessel (ATEV) Phase 3 Est. Readout
Primary completion for Acellular Tissue Engineered Vessel (ATEV) trial (NCT05908084) in End Stage Renal Disease (ESRD)
SourceMarket Overview
Stock performance and key metrics
Human Acellular Vessel (HAV)
Renal Failure
Acellular Tissue Engineered Vessel (ATEV)
End Stage Renal Disease (ESRD)
HAV
Renal Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Human Acellular Vessel (HAV) | Phase 3 | Renal Failure | - | - |
Acellular Tissue Engineered Vessel (ATEV) | Phase 3 | End Stage Renal Disease (ESRD) | - | - |
HAV | Phase 2 | Renal Failure | - | - |
Frequently asked questions
What is in Humacyte, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Humacyte, Inc.'s (HUMA) pipeline across Phase 3, Phase 2. Its lead program is Acellular Tissue Engineered Vessel (ATEV) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Humacyte, Inc.'s next FDA catalyst?→
Humacyte, Inc.'s (HUMA) next tracked catalyst is a Phase 3 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HUMA biotech catalysts?→
Add HUMA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Humacyte, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.